ISOLUTE® HYDRO DME+ columns and plates provide extremely efficient removal of matrix components and hydrolysis enzyme from urine and other biological fluid samples, using a simple pass through workflow.
Part No. | Description | Pack Size | List Price | |
---|---|---|---|---|
970-0400-PZ01 | ISOLUTE® HYDRO DME+ 400 mg Plate | 1 | 176 USD | Add to quote/cart |
970-0040-BZ | ISOLUTE® HYDRO DME+ 400 mg/3 mL Columns | 50 | 92 USD | Add to quote/cart |
Ideal for drugs of abuse and pain management applications, the inclusion of Biotage® HYDRO frit technology means that urine samples can be hydrolyzed in-situ in the column, eliminating the need for post hydrolysis sample transfer steps.
Dual Mode Extraction (DME) has been developed by Biotage to provide more effective removal of matrix components from urine (and other biological fluid samples) using a combination of liquid partitioning and scavenging modes. This novel extraction technology quickly and easily removes urinary components such as pigments, salts, urea, creatinine and residual hydrolysis enzyme, leaving the sample visually clear and reducing matrix effects. Cleaner extracts mean you can inject 2 x as many samples as D&S, without loss of sensitivity.
In addition to maintaining instrument performance, cleaner extracts mean lower LOQs than with D&S.
Because the HYDRO frit technology holds all of the sample above the sorbent bed during the elevated temperature incubation process, hydrolysis efficiency when using ISOLUTE® HYDRO DME+ is equivalent to off-line hydrolysis under the same conditions. Existing hydrolysis procedures can easily be transferred to ISOLUTE® HYDRO DME+.
Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.
Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner – HumanKind Unlimited.
Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.
Biotage is headquartered in Uppsala in Sweden and employs appr. 700 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.
Copyright © 2023 Biotage